Veracyte (VCYT) Common Equity (2012 - 2026)

Veracyte (VCYT) has 15 years of Common Equity data on file, last reported at $1.3 billion in Q1 2026.

• Quarterly Common Equity rose 12.51% year-over-year to $1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 12.51% YoY) and the FY2025 annual result came in at $1.3 billion, up 11.36% from the prior year.
• Common Equity climbed to $1.3 billion in Q1 2026 per VCYT's latest filing, from $1.3 billion in the prior quarter.
• The five-year high for Common Equity was $1.3 billion in Q1 2026, with the low at $1.0 billion in Q4 2023.
• Average Common Equity over 5 years is $1.1 billion, with a median of $1.1 billion recorded in 2024.
• Year-over-year, Common Equity declined 5.32% in 2022 and grew 12.63% in 2024.
• Veracyte's Common Equity stood at $1.1 billion in 2022, then dropped by 2.89% to $1.0 billion in 2023, then gained by 12.63% to $1.2 billion in 2024, then grew by 11.36% to $1.3 billion in 2025, then climbed by 2.66% to $1.3 billion in 2026.
• Business Quant data shows VCYT's Common Equity at $1.3 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.3 billion in Q3 2025.